相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.
T. Hickish et al.
CANCER RESEARCH (2010)
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab-induced HER Reprogramming in Resistant Breast Carcinoma Cells
Murli Narayan et al.
CANCER RESEARCH (2009)
HER-2 Signaling and Inhibition in Breast Cancer
B. C. Browne et al.
CURRENT CANCER DRUG TARGETS (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Stemming Resistance to HER-2 Targeted Therapy
Philippe L. Bedard et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2009)
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
Falm Eskens et al.
BRITISH JOURNAL OF CANCER (2008)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR
James Spicer et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Trastuzumab: triumphs and tribulations
R. Nahta et al.
ONCOGENE (2007)
A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor
R. Plummer et al.
EJC SUPPLEMENTS (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management
Thomas J. Lynch et al.
ONCOLOGIST (2007)
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
Judit Anido et al.
EMBO JOURNAL (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
